Effectiveness and impact of a reduced infant schedule of 4CMenB vaccine against group B meningococcal disease in England: a national observational cohort study

The new multicomponent vaccine against meningococcal serogroup B, 4CMenB: Immunological, functional and structural characterization of the antigens

Serruto, D., Bottomley, M. J., Ram, S., Giuliani, M. M., & Rappuoli, R. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.01.033 · Cited by 405

Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines

Donnelly, J., Medini, D., Boccadifuoco, G., Biolchi, A., Ward, J. I., Frasch, C. E., Moxon, E. R., Stella, M., Comanducci, M., Bambini, S., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1013758107 · Cited by 296

Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: a qualitative and quantitative assessment

Vogel, U. F., Taha, M., Vázquez, J. A., Findlow, J., Claus, H., Stefanelli, P., Caugant, D. A., Kriz, P., Abad, R., Bambini, S., et al. (2013) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(13)70006-9 · Cited by 283

Estimation of Vaccine Effectiveness Using the Screening Method

Farrington, P. (1993) · International Journal of Epidemiology · doi:10.1093/ije/22.4.742 · Cited by 261

Advances in the Development of Vaccines againstNeisseria meningitidis

Tan, L., Carlone, G. M., & Borrow, R. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0906357 · Cited by 233

Immunogenicity and reactogenicity in UK infants of a novel meningococcal vesicle vaccine containing multiple class 1 (PorA) outer membrane proteins

Cartwright, K. A. V., Morris, R., Rümke, H. C., Fox, A., Borrow, R., Begg, N. T., Richmond, P., & POOLMAN, J. T. (1999) · Vaccine · doi:10.1016/s0264-410x(99)00044-4 · Cited by 176

Meningococcal C conjugate vaccine: the experience in England and Wales

Campbell, H., Borrow, R., Salisbury, D., & Miller, E. (2009) · Vaccine · doi:10.1016/j.vaccine.2009.04.067 · Cited by 168

Re-evaluating cost effectiveness of universal meningitis vaccination (Bexsero) in England: modelling study

Christensen, H., Trotter, C. L., Hickman, M., & Edmunds, W. J. (2014) · BMJ · doi:10.1136/bmj.g5725 · Cited by 142

Bactericidal antibody against a representative epidemiological meningococcal serogroup B panel confirms that MATS underestimates 4CMenB vaccine strain coverage

Frosi, G., Biolchi, A., Sapio, M. L., Rigat, F., Gilchrist, S., Lucidarme, J., Findlow, J., Borrow, R., Pizza, M., Giuliani, M. M., et al. (2013) · Vaccine · doi:10.1016/j.vaccine.2013.08.006 · Cited by 137

Bexsero® chronicle

Vernikos, G. S., & Medini, D. (2014) · Pathogens and Global Health · doi:10.1179/2047773214y.0000000162 · Cited by 104

Immunization with recombinant truncated Neisseria meningitidis-Macrophage Infectivity Potentiator (rT-Nm-MIP) protein induces murine antibodies that are cross-reactive and bactericidal for Neisseria gonorrhoeae

Humbert, M. V., & Christodoulides, M. (2018) · Vaccine · doi:10.1016/j.vaccine.2018.05.069 · Cited by 20

Potential Coverage of the 4CMenB Vaccine against Invasive Serogroup BNeisseria meningitidisIsolated from 2009 to 2013 in the Republic of Ireland

Mulhall, R., Bennett, D. E., Cunney, R., Borrow, R., Lucidarme, J., Findlow, J., Jolley, K. A., Bray, J. E., Maiden, M. C. J., Moschioni, M., et al. (2018) · mSphere · doi:10.1128/msphere.00196-18 · Cited by 20

Vaccine‐preventable severe morbidity and mortality caused by meningococcus and pneumococcus: A population‐based study in France

Lorton, F., Chalumeau, M., Assathiany, R., Martinot, A., Bucchia, M., Roué, J., Bourgoin, P., Chantreuil, J., Boussicault, G., Gaillot, T., et al. (2018) · Paediatric and Perinatal Epidemiology · doi:10.1111/ppe.12500 · Cited by 20

The yin and yang of fever after meningococcal B vaccination

Ladhani, S. N., & Riordan, A. I. (2017) · Archives of Disease in Childhood · doi:10.1136/archdischild-2017-313419 · Cited by 19

Recent changes of invasive meningococcal disease in France: arguments to revise the vaccination strategy in view of those of other countries

Taha, M., Gaudelus, J., Deghmane, A., & Caron, F. (2020) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2020.1729030 · Cited by 19

Immunisation schedule of the Spanish Association of Paediatrics: 2019 recommendations

Moreno‐Pérez, D., García, F. J. Á., Aldeán, J. Á., Ortega, M. J. C., Garcés‐Sánchez, M., Sánchez, N. G., Merino, Á. H., Hernández, M. J. M., Moína, M. M., Melián, A. M., et al. (2019) · Anales de Pediatría (English Edition) · doi:10.1016/j.anpede.2018.11.001 · Cited by 18

Meningococcal vaccines in China

Xu, Y., Li, Y., Wang, S., Li, M., Xu, M., & Ye, Q. (2021) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2020.1857201 · Cited by 18

Overview of meningococcal epidemiology and national immunization programs in children and adolescents in 8 Western European countries

Cardoso, G. P., Lagrée-Chastan, M., Caséris, M., Gaudelus, J., Haas, H., Leroy, J., Bakhache, P., Pujol, J.-F., Werner, A., Dommergues, M., et al. (2022) · Frontiers in Pediatrics · doi:10.3389/fped.2022.1000657 · Cited by 18

Outcomes of Serogroup B Meningococcal Disease in Children after Implementation of Routine Infant 4cmenb Vaccination; Active Prospective National Surveillance, September 2015 - March 2021, England

Mensah, A. A., Campbell, H. J., Clark, S. A., Ribeiro, S., Lucidarme, J., Bai, X., Borrow, R., & Ladhani, S. N. (2022) · The Lancet Child & Adolescent Health · doi:10.1016/s2352-4642(22)00379-0 · Cited by 18

Estimating primary care attendance rates for fever in infants after meningococcal B vaccination in England using national syndromic surveillance data

Harcourt, S., Morbey, R., Bates, C. J., Carter, H., Ladhani, S. N., de Lusignan, S., Smith, G., & Elliot, A. J. (2017) · Vaccine · doi:10.1016/j.vaccine.2017.11.076 · Cited by 18

Safety of meningococcal group B vaccination in hospitalised premature infants

Kent, A., Beebeejaun, K., Braccio, S., Kadambari, S., Clarke, P., Heath, P. T., & Ladhani, S. N. (2018) · Archives of Disease in Childhood Fetal & Neonatal · doi:10.1136/archdischild-2017-314152 · Cited by 18

Safety of meningococcal B vaccine (4CMenB) in adolescents in Australia

Marshall, H. S., KOEHLER, A. P., Wang, B., Ahoure, M., Gold, M., Quinn, H., Crawford, N. W., Pratt, N. L., Sullivan, T., & Macartney, K. K. (2020) · Vaccine · doi:10.1016/j.vaccine.2020.07.009 · Cited by 18

Awareness, Attitudes, and Practices Toward Meningococcal B Vaccine among Pediatricians in Italy

Ferrara, P., Stromillo, L., & Albano, L. (2018) · Medicina · doi:10.3390/medicina54060100 · Cited by 17

Public health perspective of a pentavalent meningococcal vaccine combining antigens of MenACWY-CRM and 4CMenB

Bekkat-Berkani, R., Fragapane, E., Preiss, S., Rappuoli, R., Sohn, W.-Y., Soumahoro, L., & Vadivelu, K. (2022) · Journal of Infection · doi:10.1016/j.jinf.2022.09.001 · Cited by 17

Commentary: Estimation of vaccine effectiveness using the screening method

Flannery, B. L., Andrews, N. J., Feikin, D. R., & Patel, M. K. (2022) · International Journal of Epidemiology · doi:10.1093/ije/dyac013 · Cited by 17

Emerging clinical experience with vaccines against group B meningococcal disease

Wilkins, A. L., & Snape, M. D. (2017) · Vaccine · doi:10.1016/j.vaccine.2017.07.056 · Cited by 16

Multi-component meningococcal serogroup B (MenB)-4C vaccine induces effective opsonophagocytic killing in children with a complement deficiency

van den Broek, B., van Els, C. A. C. M., Kuipers, B., van Aerde, K., Henriet, S., de Groot, R., de Jonge, M. I., Langereis, J. D., & van der Flier, M. (2019) · Clinical & Experimental Immunology · doi:10.1111/cei.13368 · Cited by 16

‘Be on the TEAM’ Study (Teenagers Against Meningitis): protocol for a controlled clinical trial evaluating the impact of 4CMenB or MenB-fHbp vaccination on the pharyngeal carriage of meningococci in adolescents

Carr, J., Plested, E. L., Aley, P. K., Camara, S., Davis, K., MacLennan, J. M., Gray, S. J., Faust, S. N., Borrow, R., Christensen, H., et al. (2020) · BMJ Open · doi:10.1136/bmjopen-2020-037358 · Cited by 16

Persistence of immunity after vaccination with a capsular group B meningococcal vaccine in 3 different toddler schedules

Sadarangani, M., Sell, T., Iro, M. A., Snape, M. D., Voysey, M., Finn, A. H. R., Heath, P. T., Bona, G., Esposito, S., Díez‐Domingo, J., et al. (2017) · Canadian Medical Association Journal · doi:10.1503/cmaj.161288 · Cited by 16

Health Technology Assessment for Vaccines Against Rare, Severe Infections: Properly Accounting for Serogroup B Meningococcal Vaccination's Full Social and Economic Benefits

Stawasz, A., Huang, L., Kirby, P., & Bloom, D. E. (2020) · Frontiers in Public Health · doi:10.3389/fpubh.2020.00261 · Cited by 16

Calendario de vacunaciones de la Asociación Española de Pediatría: recomendaciones 2020

García, F. J. Á., Ortega, M. J. C., Aldeán, J. Á., Garcés‐Sánchez, M., Sánchez, N. G., Llanos, E. G., Merino, Á. H., de Arce, A. I., Moína, M. M., Melián, A. M., et al. (2020) · Anales de Pediatría · doi:10.1016/j.anpedi.2019.10.007 · Cited by 16

Epidemiology of Meningococcal Disease in Four South American Countries and Rationale of Vaccination in Adolescents from the Region: Position Paper of the Latin American Society of Pediatric Infectious Diseases (SLIPE)

Villena, R., Sáfadi, M. A. P., de Gentile, A. S., Pujadas, M., de la Maza, V., George, S., & Torres, J. P. (2023) · Vaccines · doi:10.3390/vaccines11121841 · Cited by 15

Long-term 4CMenB Vaccine Effectiveness Against Gonococcal Infection at Four Years Post–Program Implementation: Observational Case–Control Study

Wang, B., Giles, L. C., Andraweera, P. H., McMillan, M., Beazley, R., Sisnowski, J., Almond, S., Mitchell, J., Lally, N., Bell, C., et al. (2024) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofae726 · Cited by 15

Evaluation of strain coverage of the multicomponent meningococcal serogroup B vaccine (4CMenB) administered in infants according to different immunisation schedules

Biolchi, A., Tomei, S., Santini, L., Welsch, J. A., Toneatto, D., Gaitatzis, N., Bai, X., Borrow, R., Giuliani, M. M., Mori, E., et al. (2018) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2018.1537756 · Cited by 15

To LP or not to LP? Identifying the Etiology of Pediatric Meningitis

Mijović, H., & Sadarangani, M. (2019) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0000000000002313 · Cited by 15

Gene expression profiling reveals insights into infant immunological and febrile responses to group B meningococcal vaccine

O’Connor, D., Pinto, M. V., Sheerin, D., Tomić, A., Drury, R. E., Channon‐Wells, S., Galal, U., Dold, C., Robinson, H., Kerridge, S. A., et al. (2020) · Molecular Systems Biology · doi:10.15252/msb.20209888 · Cited by 15

The next chapter for group B meningococcal vaccines

Wang, N., & Pollard, A. J. (2017) · Critical Reviews in Microbiology · doi:10.1080/1040841x.2017.1329276 · Cited by 15

Restricted fluid bolus versus current practice in children with septic shock: the FiSh feasibility study and pilot RCT

Inwald, D. P., Canter, R. R., Woolfall, K., O’Hara, C. B., Mouncey, P. R., Zenasni, Z., Hudson, N., Saunders, S., Carter, A., Jones, N., et al. (2018) · Health Technology Assessment · doi:10.3310/hta22510 · Cited by 15

A world without bacterial meningitis: how genomic epidemiology can inform vaccination strategy

Rodrigues, C. M. C., & Maiden, M. C. J. (2018) · F1000Research · doi:10.12688/f1000research.13793.1 · Cited by 15

Interlaboratory comparison of a multiplex immunoassay that measures human serum IgG antibodies against six-group B streptococcus polysaccharides

Doaré, K. L., Gaylord, M. A., Anderson, A. S., Andrews, N. J., Baker, C. J., Bolcen, S. J., Felek, A., Giardina, P. C., Grube, C. D., Hall, T., et al. (2024) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2024.2330138 · Cited by 14

Safety and immunogenicity of a meningococcal B recombinant vaccine when administered with routine vaccines to healthy infants in Taiwan: A phase 3, open-label, randomized study

Chiu, N., Huang, L., Willemsen, A., Bhusal, C., Arora, A. K., Mojares, Z. R., & Toneatto, D. (2018) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2018.1425659 · Cited by 14

Meningococcal vaccination in pregnancy

Raya, B. A., & Sadarangani, M. (2018) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2018.1445447 · Cited by 14

Typing complex meningococcal vaccines to understand diversity and population structure of key vaccine antigens

Rodrigues, C. M. C., Chan, H., Vipond, C., Jolley, K. A., Harrison, O. B., Wheeler, J. X., Whiting, G. C., Feavers, I. M., & Maiden, M. C. J. (2018) · Wellcome Open Research · doi:10.12688/wellcomeopenres.14859.1 · Cited by 14

Immunogenicity and safety of the 4CMenB and MenACWY-CRM meningococcal vaccines administered concomitantly in infants: A phase 3b, randomized controlled trial

Parra, M. M., de Gentile, A. S., Narváez, J. A. V., Capdevila, A., Minguez, Á. R., Carrascal, M., Willemsen, A., Bhusal, C., & Toneatto, D. (2018) · Vaccine · doi:10.1016/j.vaccine.2018.10.096 · Cited by 15

Calendario de vacunaciones de la Asociación Española de Pediatría: recomendaciones 2019

Moreno‐Pérez, D., García, F. J. Á., Aldeán, J. Á., Ortega, M. J. C., Garcés‐Sánchez, M., Sánchez, N. G., Merino, Á. H., Hernández, M. J. M., Moína, M. M., Melián, A. M., et al. (2019) · Anales de Pediatría · doi:10.1016/j.anpedi.2018.10.006 · Cited by 14

IMMUNISATION SCHEDULE OF THE SPANISH ASSOCIATION OF PAEDIATRICS: 2020 RECOMMENDATIONS

García, F. J. Á., Ortega, M. J. C., Aldeán, J. Á., Garcés‐Sánchez, M., Sánchez, N. G., Llanos, E. G., Merino, Á. H., de Arce, A. I., Moína, M. M., Melián, A. M., et al. (2020) · Anales de Pediatría (English Edition) · doi:10.1016/j.anpede.2019.10.003 · Cited by 13

Impact and effectiveness of meningococcal vaccines: a review

de Oliveira, L. H., Jaúregui, B., Carvalho, A. F., & Giglio, N. (2017) · Revista Panamericana de Salud Pública · doi:10.26633/rpsp.2017.158 · Cited by 13

Unraveling Neisseria meningitidis pathogenesis: from functional genomics to experimental models

Soriani, M. (2017) · F1000Research · doi:10.12688/f1000research.11279.1 · Cited by 13

Neisseria meningitidis serogroup B carriage by adolescents and young adults living in Milan, Italy: Prevalence of strains potentially covered by the presently available meningococcal B vaccines

Terranova, L., Principi, N., Bianchini, S., Pietro, G. M. D., Umbrello, G., Madini, B., & Esposito, S. (2018) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2018.1450121 · Cited by 13

Parental Knowledge about Meningococcal Disease and Vaccination Uptake among 0–5 years Old Polish Children

Drozd-Dąbrowska, M., Topczewska, K., Korzeń, M., Sałacka, A., & Gańczak, M. (2019) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph16020265 · Cited by 13

Concomitant administration of meningococcal vaccines with other vaccines in adolescents and adults: a review of available evidence

Alderfer, J., Srivastava, A. K., Istúriz, R., Burman, C., Absalon, J., Beeslaar, J. F., & Perez, J. L. (2019) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2019.1581542 · Cited by 13

Comparative transcriptomics between species attributes reactogenicity pathways induced by the capsular group B meningococcal vaccine, 4CMenB, to the membrane-bound endotoxin of its outer membrane vesicle component

Sheerin, D., O’Connor, D., Dold, C., Clutterbuck, E., Attar, M., Rollier, C. S., Sadarangani, M., & Pollard, A. J. (2019) · Scientific Reports · doi:10.1038/s41598-019-50310-0 · Cited by 13

Evaluating the effectiveness of the 4CMenB vaccine against invasive meningococcal disease and gonorrhoea in an infant, child and adolescent program: protocol

Marshall, H. S., Andraweera, P. H., Wang, B., McMillan, M., Koehler, A. P., Lally, N., Almond, S., Denehy, E., Ahoure, M., Giles, L. C., et al. (2021) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2020.1827614 · Cited by 13

Community-acquired acute bacterial meningitis in adults: a clinical update

Ellis, J., Luintel, A., Chandna, A., & Heyderman, R. S. (2019) · British Medical Bulletin · doi:10.1093/bmb/ldz023 · Cited by 12

Immune interface interference vaccines: An evolution‐informed approach to anti‐bacterial vaccine design

Croucher, N. J. (2024) · Microbial Biotechnology · doi:10.1111/1751-7915.14446 · Cited by 12

4CMenB vaccine effectiveness: reasons for optimism

Basta, N. E., & Christensen, H. (2016) · The Lancet · doi:10.1016/s0140-6736(16)32061-x · Cited by 12

Potential benefits of using a multicomponent vaccine for prevention of serogroup B meningococcal disease

Watson, P. S., Novy, P., & Friedland, L. R. (2019) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2019.05.019 · Cited by 12

Meningococcal vaccines in Australia: a 2019 update

Sharma, K., Chiu, C., & Wood, N. (2019) · Australian Prescriber · doi:10.18773/austprescr.2019.042 · Cited by 12

A re-assessment of 4CMenB vaccine effectiveness against serogroup B invasive meningococcal disease in England based on an incidence model

Argante, L., Abbing‐Karahagopian, V., Vadivelu, K., Rappuoli, R., & Medini, D. (2021) · BMC Infectious Diseases · doi:10.1186/s12879-021-06906-x · Cited by 12

Invasive meningococcal disease epidemiology and vaccination strategies in four Southern European countries: a review of the available data

Zografaki, I., Detsis, M., del Amo, M., Iantomasi, R., Maia, A., Montuori, E. A., & Méndez, C. (2023) · Expert Review of Vaccines · doi:10.1080/14760584.2023.2225596 · Cited by 12

Optimizing the timing of 4CMenB vaccination in adolescents and young adults based on immune persistence and booster response data

Watson, P. S., Novy, P., Bekkat-Berkani, R., Strubbe, F., & Banzhoff, A. (2019) · Expert Review of Vaccines · doi:10.1080/14760584.2019.1580579 · Cited by 12

Distribution of Neisseria meningitidis serogroup b (NmB) vaccine antigens in meningococcal disease causing isolates in the United States during 2009–2014, prior to NmB vaccine licensure

Chang, H.-Y., Vuong, J. T., Hu, F., Liberator, P., Chen, A., Kretz, C. B., Blain, A. E., Li, H., Retchless, A. C., Whaley, M. J., et al. (2019) · Journal of Infection · doi:10.1016/j.jinf.2019.09.001 · Cited by 12

Epidemiology and Control of Meningococcal Disease in Canada: A Long, Complex, and Unfinished Story

Wals, P. D. (2019) · Canadian Journal of Infectious Diseases and Medical Microbiology · doi:10.1155/2019/8901847 · Cited by 12

Cost-effectiveness of alternative strategies for vaccination of adolescents against serogroup B IMD with the MenB-FHbp vaccine in Canada

Breton, M.-C., Huang, L., Snedecor, S. J., Cornelio, N., & Fanton-Aita, F. (2020) · Canadian Journal of Public Health · doi:10.17269/s41997-019-00275-4 · Cited by 11

Genomic surveillance of Neisseria meningitidis serogroup B invasive strains: Diversity of vaccine antigen types, Brazil, 2016-2018

de Lemos, A. P. S., Sacchi, C. T., Gonçalves, C. R., Camargo, C. H., & Andrade, A. L. (2020) · PLoS ONE · doi:10.1371/journal.pone.0243375 · Cited by 11

Outbreak strain characterisation and pharyngeal carriage detection following a protracted group B meningococcal outbreak in adolescents in South-West England

Clark, S. A., Lucidarme, J., Angel, G., Lekshmi, A., Morales‐Aza, B. M., Willerton, L., Campbell, H. J., Gray, S. J., Ladhani, S. N., Wade, M., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-46483-3 · Cited by 11

Evaluación económica de la inclusión en el calendario vacunal de 4CMenB (Bexsero®) en España

Ruiz-Montero, R., Epstein, D. M., Guzmán-Herrador, B., & Espín, J. (2019) · Gaceta Sanitaria · doi:10.1016/j.gaceta.2019.08.007 · Cited by 11

Genomic Characterization of Invasive Meningococcal Serogroup B Isolates and Estimation of 4CMenB Vaccine Coverage in Finland

Bodini, M., Brozzi, A., Giuliani, M., Nohynek, H., Vainio, A., Kuusi, M., Paola, R. D., Pizza, M., Medini, D., Toropainen, M., et al. (2020) · mSphere · doi:10.1128/msphere.00376-20 · Cited by 11

Immunogenicity and safety of different schedules of the meningococcal ABCWY vaccine, with assessment of long-term antibody persistence and booster responses – results from two phase 2b randomized trials in adolescents

Vesikari, T., Brzostek, J., Ahonen, A., Paassilta, M., Majda-Stanisławska, E., Szenborn, L., Virta, M., Clifford, R. A., Jackowska, T., Kimmel, M. A., et al. (2021) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2021.1968214 · Cited by 11

The life-and-death struggle between the complement system and pathogens: Mechanisms of elimination, evasion tactics, and translational potential

Lian, S., Liu, J., Yang, Y., Zhu, G., & Xia, P. (2025) · Virulence · doi:10.1080/21505594.2025.2553781 · Cited by 10

Meningococcal arthritis and myopericarditis: a case report

Steele, L., Bechman, K., de Barra, E., & Mackworth-Young, C. G. (2017) · BMC Infectious Diseases · doi:10.1186/s12879-017-2845-3 · Cited by 10

Missed vaccinations and critical care admission: all you may wish to know or rediscover—a narrative review

Pittet, L. F., Abbas, M., Siegrist, C., & Pittet, D. (2019) · Intensive Care Medicine · doi:10.1007/s00134-019-05862-0 · Cited by 11

A critical analysis of serogroup B meningococcal disease burden in Brazil (2001–2015): implications for public health decisions

Chicuto, L. A. D., de Moraes, C., de Moraes, J. C., & Sáfadi, M. A. P. (2020) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2019.1700710 · Cited by 10

Meningococcal Capsular Group B Vaccines

Granoff, D. M., Pollard, A. J., & Harrison, L. H. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-35761-6.00053-5 · Cited by 10

Unlocking the potential of bacterial membrane vesicles: Advances in isolation techniques and biomedical applications

Canalejo-Marco, G., Arruebo, M., & Sebastián, V. (2025) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2025.115235 · Cited by 10

Prophylactic Paracetamol After Meningococcal B Vaccination Reduces Postvaccination Fever and Septic Screens in Hospitalized Preterm Infants

Dubus, M., Ladhani, S. N., & Vasu, V. (2019) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0000000000002507 · Cited by 9

Health impact and cost-effectiveness of introducing the vaccine (Bexsero) against MenB disease into the Brazilian immunization programme

Silveira, M. M., McBride, A. J. A., & Trotter, C. L. (2019) · Vaccine · doi:10.1016/j.vaccine.2019.09.062 · Cited by 9

Does vaccination with 4CMenB convey protection against meningococcal serogroup B strains not predicted to be covered by MATS? A study of the UK clonal complex cc269

Stella, M., Giuliani, M., Biolchi, A., Tomei, S., Paola, R. D., Bai, X., Borrow, R., Lucidarme, J., Gaetana, R. L., Toneatto, D., et al. (2019) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2019.1688039 · Cited by 9

Strain coverage of Bexsero vaccine assessed by whole-genome sequencing over a cohort of invasive meningococci of serogroups B and W isolated in Switzerland

Léo, S., Lazarević, V., Girard, M., Velasco, G. C. G.-J., Gaïa, N., Renzi, G., Cherkaoui, A., Hong, E., Taha, M., & Schrenzel, J. (2020) · Vaccine · doi:10.1016/j.vaccine.2020.05.071 · Cited by 9

Good News and Bad News — 4CMenB Vaccine for Group B Neisseria meningitidis

Harrison, L. H., & Stephens, D. S. (2020) · New England Journal of Medicine · doi:10.1056/nejme1916440 · Cited by 9

Immunogenicity of a single 4CMenB vaccine booster in adolescents 11 years after childhood immunisation

Rollier, C. S., Dold, C., Blackwell, L., Linder, A., Silva-Reyes, L., Clutterbuck, E., Davis, K., Ford, K. J., Liu, X., Holland, A., et al. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.04.085 · Cited by 8

Growing evidence supports 4CMenB effectiveness

Ladhani, S. N., Borrow, R., & Andrews, N. J. (2018) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(18)30051-3 · Cited by 8

Cross-Reactive Bactericidal Antimeningococcal Antibodies Can Be Isolated From Convalescing Invasive Meningococcal Disease Patients Using Reverse Vaccinology 2.0

Bidmos, F. A., Nadel, S., Screaton, G. R., Kroll, J. S., & Langford, P. R. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01621 · Cited by 8

Protocol for a controlled human infection with genetically modifiedNeisseria lactamicaexpressing the meningococcal vaccine antigen NadA: a potent new technique for experimental medicine

Gbesemete, D. F., Laver, J. R., de Graaf, H., Ibrahim, M., Vaughan, A., Faust, S. N., GORRINGE, A. R., & Read, R. C. (2019) · BMJ Open · doi:10.1136/bmjopen-2018-026544 · Cited by 8

Cocrystal structure of meningococcal factor H binding protein variant 3 reveals a new crossprotective epitope recognized by human mAb 1E6

Bianchi, F., Veggi, D., Santini, L., Buricchi, F., Bartolini, E., Surdo, P. L., Martinelli, M., Finco, O., Masignani, V., Bottomley, M. J., et al. (2019) · The FASEB Journal · doi:10.1096/fj.201900374r · Cited by 8

Meningococcal Serogroup B Disease in Vaccinated Children

Soler‐Garcia, A., de Sevilla, M. F., Abad, R., Esteva, C., Alsina, L., Vázquez, J. A., Muñoz‐Almagro, C., & Noguera‐Julián, A. (2019) · Journal of the Pediatric Infectious Diseases Society · doi:10.1093/jpids/piz071 · Cited by 8

Challenges in synthesis of real-world vaccine effects on meningococcal serogroup B disease for 4CMenB vaccine post-licensure effectiveness studies: A systematic review

Cinconze, E., Rosillon, D., Rappuoli, R., Vadivelu, K., Bekkat-Berkani, R., & Abbing‐Karahagopian, V. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.05.025 · Cited by 7

Characterisation and Immunogenicity of Neisseria cinerea outer membrane vesicles displaying NadA, NHBA and fHbp from Neisseria meningitidis serogroup B

Manoharan, S., Farman, T. A., Piliou, S., & Mastroeni, P. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1473064 · Cited by 7

Immunogenicity and Reactogenicity of a Reduced Schedule of a 4-component Capsular Group B Meningococcal Vaccine: A Randomized Controlled Trial in Infants

Pinto, M. V., O’Connor, D., Galal, U., Clutterbuck, E., Robinson, H., Plested, E. L., Bibi, S., Camara, S., Hughes, H., Kerridge, S. A., et al. (2020) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofaa143 · Cited by 7

Global Epidemiology of Vaccine-preventable Bacterial Meningitis

Syrogiannopoulos, G. A., Michoula, A. N., & Grivea, I. N. (2022) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0000000000003629 · Cited by 7

Protecting UK adolescents and adults against meningococcal serogroup B disease

Vyse, A., Ellsbury, G., & Madhava, H. (2018) · Expert Review of Vaccines · doi:10.1080/14760584.2018.1432360 · Cited by 7

Two centuries of immunisation in the UK (part 1)

Lang, S., Loving, S., McCarthy, N. D., Ramsay, M. E., SALISBURY, D. M., & Pollard, A. J. (2019) · Archives of Disease in Childhood · doi:10.1136/archdischild-2019-317314 · Cited by 7

Meningitis vaccines in children: what have we achieved and where next?

McAlpine, A., & Sadarangani, M. (2019) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0000000000000580 · Cited by 7

The epidemiology of invasive meningococcal disease and the utility of vaccination in Malta

Pace, D., Gauci, C., & Barbara, C. (2020) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-020-03914-8 · Cited by 7

Translating meningococcal serogroup B vaccines for healthcare professionals

Sáfadi, M. A. P., Martinón‐Torres, F., Serra, L., Burman, C., & Presa, J. V. (2021) · Expert Review of Vaccines · doi:10.1080/14760584.2021.1899820 · Cited by 7

Two centuries of immunisation in the UK (part II)

Lang, S., Loving, S., McCarthy, N. D., Ramsay, M. E., SALISBURY, D. M., & Pollard, A. J. (2019) · Archives of Disease in Childhood · doi:10.1136/archdischild-2019-317707 · Cited by 7

Calendario de vacunaciones de la Asociación Española de Pediatría (CAV-AEP): recomendaciones 2018

Moreno‐Pérez, D., García, F. J. Á., Aldeán, J. Á., Ortega, M. J. C., Garcés‐Sánchez, M., Sánchez, N. G., Merino, Á. H., Hernández, M. J. M., Moína, M. M., Melián, A. M., et al. (2018) · Anales de Pediatría · doi:10.1016/j.anpedi.2017.10.001 · Cited by 7

Risk of Invasive Meningococcal Disease in Preterm Infants

Calvert, A., Campbell, H. J., Heath, P. T., Jones, C. E., Doaré, K. L., Mensah, A. A., & Ladhani, S. N. (2024) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofae164 · Cited by 6

Bacterial extracellular vesicles as bioactive nanocarriers for wound treatment

Shi, Y., Zheng, Z., Li, Y., Wang, Y., Azevedo, H. S., Liu, X., Zhang, C., & Hu, H. (2026) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2026.01.007 · Cited by 6

Optimal use of meningococcal serogroup B vaccines: moving beyond outbreak control

Balmer, P., & York, L. J. (2018) · Therapeutic Advances in Vaccines and Immunotherapy · doi:10.1177/2515135518781757 · Cited by 6

Blood biomarkers in early bacterial infection and sepsis diagnostics in feverish young children

Dagys, A., Laucaitytė, G., Volkevičiūtė, A., Abramavičius, S., Kėvalas, R., Vitkauskienė, A., & Jankauskaitė, L. (2022) · International Journal of Medical Sciences · doi:10.7150/ijms.69859 · Cited by 6

Nigeria introduces the world’s first Men5 CV meningitis vaccine

Aderinto, N., Olatunji, G. D., Kokori, E., Ogieuhi, I. J., Alao, A. E., Ajimotokan, O. I., Okam, O. V., Akinruli, O. A., & Olawoyin, M. T. (2025) · Discover Public Health · doi:10.1186/s12982-025-00592-9 · Cited by 5

Vaccines against Neisseria meningitidis serogroup B strains – What does genomics reveal on the Portuguese strain’s coverage

Bettencourt, C. R., Nogueira, P., Gomes, J. P., & Simões, M. J. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.06.038 · Cited by 5

Immunisation schedule of the Spanish Association of Paediatrics: 2018 recommendations

Moreno‐Pérez, D., García, F. J. Á., Aldeán, J. Á., Ortega, M. J. C., Garcés‐Sánchez, M., Sánchez, N. G., Merino, Á. H., Hernández, M. J. M., Moína, M. M., Melián, A. M., et al. (2018) · Anales de Pediatría (English Edition) · doi:10.1016/j.anpede.2017.11.001 · Cited by 5

Does post-implementation vaccine effectiveness data support pre-implementation predictions of 4CMenB utility?

Findlow, J., & Borrow, R. (2017) · Pathogens and Disease · doi:10.1093/femspd/ftx025 · Cited by 5

Liposomes or traditional adjuvants: induction of bactericidal activity by the macrophage infectivity potentiator protein (Mip) of Neisseria meningitidis

Costoya, L., Marzoa, J., Ferreirós, C. M., & Criado, M. T. (2017) · Apmis · doi:10.1111/apm.12709 · Cited by 5

Meningococcal B Vaccines as a Paradigm of Safe and Effective Vaccines for Children

Tome, M. G., Gonzalez‐Quevedo, R., dos Santos, M. E., Dornbusch, H. J., Straus, S. M. J. M., & Cooke, E. (2025) · Vaccines · doi:10.3390/vaccines13070770 · Cited by 4

Bacterial Extracellular Vesicles in Biomedical Research and Clinical Translation

Arce‐Rodríguez, A., Noya, J. D. L. P., & Acuña, J. M. B. (2026) · Microbial Biotechnology · doi:10.1111/1751-7915.70350 · Cited by 4

La enfermedad meningocócica y las vacunas: algunas respuestas y todavía muchas preguntas

Godoy, P., Castilla, J., Astray, J., Tuells, J., Barrabeig, I., & Domı́nguez, Á. (2019) · Gaceta Sanitaria · doi:10.1016/j.gaceta.2019.09.004 · Cited by 4

Vaccination in old age: Challenges and promises

Caruso, C., Aiello, A., Pawelec, G., & Ligotti, M. E. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-822569-1.00020-2 · Cited by 4

Vaccination of Infants with Meningococcal Group B Vaccine (4CMenB) in England

Ladhani, S. N., Andrews, N. J., Parikh, S. R., Campbell, H. J., White, J. M., Edelstein, M. L., Bai, X., Lucidarme, J., Borrow, R., & Ramsay, M. E. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1901229 · Cited by 215

Outcomes of Serogroup B Meningococcal Disease in Children after Implementation of Routine Infant 4cmenb Vaccination; Active Prospective National Surveillance, September 2015 - March 2021, England

Mensah, A. A., Campbell, H. J., Clark, S. A., Ribeiro, S., Lucidarme, J., Bai, X., Borrow, R., & Ladhani, S. N. (2022) · The Lancet Child & Adolescent Health · doi:10.1016/s2352-4642(22)00379-0 · Cited by 18

Effectiveness and Impact of the 4CMenB Vaccine against Group B Meningococcal Disease in Two Italian Regions Using Different Vaccination Schedules: A Five-Year Retrospective Observational Study (2014–2018)

Azzari, C., Moriondo, M., Nieddu, F., Guarnieri, V., Lodi, L., Canessa, C., Indolfi, G., Giovannini, M., Napoletano, G., Russo, F., et al. (2020) · Vaccines · doi:10.3390/vaccines8030469 · Cited by 68

Too Many 'Too Young to Be Vaccinated': An Observational Cohort and Case-Control Study of 4CMenB Vaccine Effectiveness and Impact Against Serogroup B Meningococcal Disease in ItalyPreprint

Lodi, L., Barbati, F., Amicizia, D., Baldo, V., Barbui, A. M., Bondi, A., Costantino, C., Dadalt, L., Ferrara, L., Fortunato, F., et al. (2023) · SSRN Electronic Journal · doi:10.2139/ssrn.4366840

P-1498. Real-World Vaccine Effectiveness and Impact of the 4CMenB Vaccine in Infants, Children, and Adolescents: A Systematic Literature Review

Marijic, P., Gaianu, L., Mathur, G., Pinto, T., Andani, A., Ladak, R., Kuylen, E., Szewczyk, K., Olewinska, E., Smela, B., et al. (2026) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofaf695.1682